CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 248 enrolled
Drug / intervention
Cotadutide 100 micrograms +4 moredrug
Likely dose
Cotadutide 100 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04515849
NCT04515849Phase 2Completed
CompareCT.gov

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

AstraZeneca·interventional·Posted Aug 17, 2020·Updated Jan 17, 2025

In Brief

A Phase 2 clinical trial evaluating Cotadutide 100 micrograms, Cotadutide 300 micrograms, and 3 other interventions for Type 2 Diabetes Mellitus and Chronic Kidney Diseases. Completed, enrolled 248 participants across 83 sites in 8 countries.

Detailed Summary

A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Chronic Kidney Diseases
CountriesAustralia, Canada, Germany, Japan, New Zealand, Poland, Spain, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 17, 2020
Enrollment StartAug 31, 2020
Primary CompletionMar 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago

Interventions

Cotadutide 100 microgramsdrug

Cotadutide 100 micrograms administered subcutaneously

Cotadutide 300 microgramsdrug

Cotadutide 300 micrograms administered subcutaneously

Cotadutide 600 microgramsdrug

Cotadutide 600 micrograms administered subcutaneously

Semaglutidedrug

Semaglutide 1.0 miligrams administered subcutaneously

Placebodrug

Placebo administered subcutaneously